SCHEMBL4194352

SCHEMBL4194352

O=C(O)Cc1cccc(OCCc2nc(-c3ccc(OC(F)(F)F)cc3)co2)c1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.41
CYP4A11 Q02928 2/20 0.41
PPARG P37231 3/20 0.41
PPARA Q07869 3/20 0.41
PLA2G4B P0C869 1/20 0.40
PPARD Q03181 4/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
GCGR P47871 2/20 0.39
P2RY14 Q15391 1/20 0.39
SUCNR1 Q9BXA5 1/20 0.39
NR1H4 Q96RI1 2/20 0.39
FFAR1 O14842 2/20 0.38
PTPN11 Q06124 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4173695 0.90 PPARA (0.45) CYP4F2CYP4A11PPARGPPARAPPARD
SCHEMBL4183405 0.85 PPARA (0.44) CYP4F2CYP4A11PPARGPPARAPLA2G4B
SCHEMBL4183437 0.84 NR1H4 (0.41) PPARGPPARAPPARDGCGRNR1H4
SCHEMBL4394323 0.79 PPARG (0.61) PPARGPPARAPPARD
SCHEMBL4181320 0.78 NR1H4 (0.38) PPARGPPARAPPARDSUCNR1NR1H4
SCHEMBL4059413 0.76 PPARG (0.50) PPARGPPARAPPARDNR1H4
SCHEMBL4064926 0.76 PPARG (0.53) PPARGPPARAPPARD
SCHEMBL4056941 0.75 PPARG (0.48) PPARGPPARAPLA2G4BPPARDPTPN11
SCHEMBL4391062 0.75 PPARG (0.61) PPARGPPARAPPARD
SCHEMBL4173723 0.73 S1PR1 (0.46) SUCNR1S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192203-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2009-07-30 US claimed
EP-1945620-A2 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2008-07-23 EP claimed
WO-2007056366-A2 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-05-18 WO claimed
US-20090192203-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2009-07-30 US disclosed
US-20090192203-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2009-07-30 US disclosed
US-20090192203-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2009-07-30 US disclosed
EP-1945620-A2 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2008-07-23 EP disclosed
WO-2007056366-A2 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-05-18 WO disclosed
WO-2007056366-A2 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192203-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS PPARG, PPARA, PPARD CYP4F2 1191/4885CYP4A11 430/4885PPARG 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.